Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety and tolerability study of linerixibat for cholestatic pruritus in primary biliary cholangitis
CTR20222331Phase 3Active
- Sponsor
- N.A./ 葛兰素史克（中国）投资有限公司
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of linerixibat in primary biliary cholangitis (PBC), sponsored by N.A./ 葛兰素史克（中国）投资有限公司. Started Mar 2023; status: active.
02
Drugs
linerixibat
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on CTR20222331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222331.